Chinese herbal medicine (CHM) has been widely used as an adjunct to western medicine in treating angina in China. We carried out this systematic review to evaluate the effectiveness of CHM on top of western medicine for angina. This meta-analysis included 46 randomized control trials with 4212 patients. For trials that included stable angina patients, the CHM group had significant lower incidence of total heart events (relative risk(RR)=0.50, 95% confidence interval (CI) 0.33–0.78), myocardial infarction (RR=0.32, 95% CI 0.14–0.72), heart failure (RR=0.37, 95% CI 0.15–0.91), and angina (RR=0.46, 95% CI 0.30–0.71) than that of control group. For trials that included unstable angina patients, CHM led to significantly lower occurrence of total heart events (RR=0.46, 95% CI 0.32–0.66), myocardial infarction (RR=0.37, 95% CI 0.26–0.54), and angina (RR=0.36, 95%CI 0.26–0.51). Likewise, for trials that included stable or unstable angina patients, the rates of myocardial infarction (RR=0.34, 95% CI 0.17–0.68) and angina (RR=0.46, 95% CI 0.30–0.70) in CHM group were significantly lower than that in control group. In conclusion, CHM is very likely to be able to improve the survival of angina patients who are already receiving western medicine.
The Therapeutic Efficacy of Chinese Patent Medicine Combined With Routine Western Medicine in the Treatment of COVID-19: A Systematic Review and Meta-Analysis
